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presented in Table 1. Some of these changes were pre- In Response to Fakruddin et al.
dicted to result in substitutions of amino acids at the and Apostolou et al.corresponding positions in the protein sequence. In
each of these cases, individual tumor DNA samples pos-
sessed the same sequence as that of the corresponding
cell line. We agree with many of the above findings, including
To determine if the divergent sequences represented the frequency and nature of BCL10 polymorphisms.
mutations of the BCL10 gene or polymorphisms, a panel However, it appears that some BCL10 abnormalities
of 50 normal genomic DNA samples from the general may be found only in RNA and not genomic DNA, sug-
population was screened (data not shown). The nucleo- gesting that BCL10 may undergo posttranscriptional se-
tide alteration in exon 1 seen in 18 MMs (Table 1) was quence modification.
assumed to be a polymorphism, because it was ob- Wild-type BCL10 is proapoptotic and behaves as a
served in numerous MMs and a control sample, and it tumor suppressor gene (Koseki et al., 1999; Thome et
did not predict an amino acid change. Thus, this variant al., 1999; Willis et al., 1999; Yan et al., 1999; Zhang
was not studied further. The nucleotide change in exon et al., 1999). BCL10 sequence abnormalities were first
1 (nucleotide 13) of Meso 38 destroys an AciI restriction detected in cDNA clones from a MALT lymphoma with
enzyme site. Restriction enzyme analysis revealed that t(1;14) and were unusually heterogeneous. An identical
three of 50 samples from the general population do not spectrum of cDNA abnormalities has been detected in
possess this AciI site, which corresponds to an allele other t(1;14) MALT lymphomas (Zhang et al., 1999), mak-
frequency of 3%. The nucleotide alteration in exon 3 ing it unlikely that all these changes represented RT,
(nucleotide 638) of Meso 17 and Meso 59 does not occur PCR, or cloning artifacts.
at a restriction enzyme site. Therefore, we performed We initially sequenced cDNA clones from 6 malignant
SSCP analysis on these two MMs and 50 normal DNA cell lines, including Tera-1, Tera-2, and GCT-44 and
samples. Nine of 50 DNA samples from normal individu- three mesothelioma lines, and in each, BCL10 abnormal-
als (allele frequency, 9%) displayed banding patterns ities were detected (Table 2 of Willis et al., 1999). Addi-
identical to those observed in Meso 17 and Meso 59 tional cDNA clones from Tera-2, a cell line that exhibits
(Table 1). Thus, we conclude that all of the nucleotide
differences detected in our MM cell lines and tumors Table 1. Summary of Tera-2 BCL10 cDNA Data
represent polymorphisms in the general population. We
Predicteddid not observe any of the nucleotide alterations re-
Homopoly- Splice Proteinported by Willis et al. (1999). Therefore, it would be
Clone Point Mutations meric Varia- (amino
important to determine if any of their alterations are # (codon) Runs tions acids)
polymorphisms.
(A) Normal CloneFinally, we performed sequence analysis on DNA from
1 nil nil nil 233 wild
PBL samples matched to the three cell lines (Mesos 17, type
38, and 59) that exhibited nucleotide changes predicting (B) Clones with Insertions/Deletions within the Homopolymeric
amino acid substitutions. The identical nucleotide se- Runs Alone
2 nil 499 ins TT nil 172quence was observed in DNA from both tumor and nor-
3 nil 499 ins T nil 168mal tissues from the same individual, indicating that
4 nil 136 del Athese base changes are representative of the constitu-
499 ins T nil 68
tional (inherited) genome in each case. In conclusion,
(C) Mutated Clones 1/2 Other AbnormalitiesBCL10 is not mutated or abnormally expressed in MM,
5 N93S AAC→AGC nil nil 233and this gene can be ruled out as a candidate for the
6 N93S AAC→AGC
1p22 TSG in this malignancy. del A codon 149 nil nil 171
7 H40H CAT→CAC silent
K45Q AAA→CAA nil nil 233Sinoula Apostolou,* Assunta De Rienzo,*
8 M153V ATG→GTG
Siva S. Murthy,* Suresh C. Jhanwar,² L177L CTA→CTG silent
and Joseph R. Testa*³ A200A GCT→GCC silent nil nil 233
9 R58Q CGA→CAA*Fox Chase Cancer Center
S218F TCT→TTT nil nil 233Philadelphia, Pennsylvania 19111
10 R58Q CGA→CAA²Memorial Sloan-Kettering Cancer Center
T168T ACT→ACC silentNew York, New York 10021
S218F TCT→TTT nil nil 233
11 H40R CAT→CGT
L41L CTA→CTT silent³ To whom correspondence should be addressed (e-mail: jr_testa@
N217S AAC→AGC 499 ins T nil 168fccc.edu).
12 A20T GCC→ACC
V26V GTA→GTG silent
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types of deviation from the wild-type sequence ob-
served in our own and others' studies (Zhang et al.,
1999):
(A) BCL10 utilized three alternative splice sites at the
exon 3/4 boundary, two of which result in deletion of
either 16 or 33 base pairs from wild-type sequence.
These splice variants were detected as different-sized
PCR products.
(B) Nucleotide insertions and deletions were common,
particularly within the homopolymeric runs of 8 A's and
7 T's. The homopolymeric runs were also sites of point
mutation (Figure 1B). In some instances, abnormalities
within these runs were seen by direct cDNA sequencing,
indicating they comprised a common transcript (Figure
1D). These data preclude cloning artifacts. In compari-
son, from 500 genomic sequences obtained in our labo-
ratories, only 4 cases exhibited deletions or insertions
within the two homopolymeric runs. These data suggest
that such changes are largely nontemplated and may
constitute an unusual form of RNA editing.
(C) Point mutations were multiple and ongoing. Whether
all point mutations are present in genomic DNA or
whether some are nontemplated is not yet clear.
These cDNA abnormalities appeared with comparable
frequency irrespective of reverse transcriptase, DNA
polymerase, or sequencing method used. A BCL10
pseudogene has not been identified by FISH, Southern,
or genomic PCR experiments.
In summary, at least some of the discrepancies be-
tween our initial data and those reported above can be
ascribed to our use of cDNA rather than genomic DNA
and to possible posttranscriptional modification of
Figure 1. Reverse BCL10 cDNA Sequences Showing Presence of BCL10. However, our analysis of genomic DNA from
Alterations within both Homopolymeric Runs
primary tumors continues to demonstrate BCL10 muta-
(A) Clone from normal lymphocytes showing 8 A's.
tions in some tumor types (H. P. et al., submitted). The(B) Direct sequencing of cDNA from patient with B cell precursor
reasons for this discrepancy are not clear but may in-acute leukemia showing complex aberrations within the 8 A's includ-
clude the ongoing nature of BCL10 mutations and theing deletion of two adenines and A→G point mutation.
(C) Direct sequencing of cDNA from myeloma cell line showing presence of individual BCL10 mutations within only a
normal run of 7 T's. subset of tumor cells.
(D) Direct sequence of cDNA from normal human fetal brain mRNA All sequences will be available via ,http://www.icr.ac.
(Clontech) showing presence of additional thymidine in about 50%
uk/haemcyto/bcldata/index.html..of the transcripts (arrow).
Note loss of readable sequence in lanes B and D subsequent to
inserted or deleted nucleotides. RT and PCR reactions performed as Martin J. S. Dyer,*³ Helen P. Price,*
described (Willis et al., 1999). Poly(A)1 RNA was reverse transcribed
Dalal M. Jadayel,* Milena Gasco,*using Superscript II (GIBCO±BRL) or rTth (Amersham) and random
Amanda R. Perry,* Rifat A. Hamoudi,*hexamers and the BCL10 open reading frame amplified using either
Tony G. Willis,* Huaizheng Peng,²Taq or Pfu polymerase with forward primer: 59-CCTCCTCTCCTTCT
TCCCCATTACC-39 and reverse primer 59-GCAATAAAGTGTCATTGT Ming-Qing Du,² and Peter G. Isaacson²
CTGGAAACAGT-39. RT-PCR products were either sequenced di- * Institute of Cancer Research, Sutton
rectly or cloned into pCR2.1 (Invitrogen). Clones were sequenced Academic Haematology and Cytogenetics
in both directions using either Licor (MWG-Biotech, Germany) or
Haddow LaboratoriesABI-377 (Applied Biosystems) automated sequencers.
Institute of Cancer Research
Sutton, Surrey SM2 5NG
United Kingdom
no genomic PCR-SSCP abnormalities, showed (Table ²University College London Medical School
1): (1) all clones had different sequences; (2) multiple London WC1E 6JJ
abnormalities in some clones; (3) no obvious clonal rela- United Kingdom
tionship between all clones; and (4) abnormalities within
the homopolymeric runs in 4/13 clones.
³ To whom correspondence should be addressed (e-mail: mdyer@We have now sequenced either RT-PCR products
icr.ac.uk).
and/or multiple cDNA clones from 18 malignant cell
lines, 48 primary lymphoid tumors, and peripheral blood
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